In reply: Henderson and McCombe describe a patient to highlight an issue raised in a recent editorial:1 that patients with motor neurone disease (MND) may develop abnormal liver function tests for reasons other than riluzole therapy. In their patient, riluzole was prescribed for a year and liver function test results remained stable. Deterioration in liver function coincided with the introduction of naltrexone. Ultimately, riluzole, an established MND therapy, had to be ceased.
The full article is accessible to AMA
members and paid subscribers.
Login to MJA or subscribe now.
- Institute of Neurological Sciences, Prince of Wales Hospital, Barker Street, Randwick, NSW 2031.
Correspondence: M.kiernan@unsw.edu.au
- 1. Kiernan MC. Riluzole: a glimmer of hope in the treatment of motor neurone disease. Med J Aust 2005; 182: 319-320. <MJA full text>
- 2. MacLennan A, Wilson DH, Taylor AW. Prevalence and cost of alternative medicine in Australia. Lancet 1996; 347: 569-573.
- 3. Wasner M, Klier H, Borasio GD. The use of alternative medicine by patients with amyotrophic lateral sclerosis. J Neurol Sci 2001; 191: 151-154.
- 4. Dwyer JM. Good medicine and bad medicine: science to promote the convergence of “alternative” and orthodox medicine. Med J Aust 2004; 180: 647-648. <MJA full text>
- 5. Dobson R. An exceptional man. BMJ 2002; 324: 1478.
Online responses are no longer available. Please refer to our instructions for authors page for more information.